查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1782152

疫苗市場機會、成長動力、產業趨勢分析及 2025 - 2034 年預測

Vaccines Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034
出版日期: | 出版商: Global Market Insights Inc. | 英文 210 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

2024年，全球疫苗市場規模達764億美元，預計2034年將以7.1%的複合年成長率成長，達到1,458億美元。這一成長主要得益於肝炎、季節性流感和新型病毒株等傳染病的不斷湧現。由於這些疾病持續威脅公共衛生，各國政府和衛生組織正在加強免疫接種力度，以降低感染率。公共支持性措施、發展中地區醫療預算的增加以及疫苗研發的進步，持續為疫苗市場擴張創造了有利的環境。此外，全球聯合疫苗的興起（單劑即可獲得針對多種疾病的免疫力），正在加速疫苗創新，簡化免疫接種方案。

疫苗市場 - IMG1

針對癌症、慢性感染和自體免疫疾病等複雜疾病的新一代疫苗的開發正在拓展市場的治療範圍。日益成長的老齡化人口（尤其是在已開發國家）仍然極易受到感染，這進一步刺激了全球疫苗需求。私人企業與公共衛生機構之間的緊密合作，加上mRNA和重組蛋白平台等不斷發展的技術，正在提升疫苗的效力、遞送和可及性。這些因素共同增強了市場的長期發展動能。

市場範圍
起始年份 2024
預測年份 2025-2034
起始值 764億美元
預測值 1458億美元
複合年成長率 7.1%

2024年，亞單位疫苗市場規模為376億美元，預計2034年將達到707億美元，複合年成長率為6.9%。此類疫苗包括重組疫苗、多醣體疫苗和結合疫苗，每種疫苗都能在不使用完整病原體的情況下增強免疫原性。它們能夠靶向致病菌中的特定蛋白質，從而提高安全性並減少不必要的免疫反應。由於亞單位疫苗具有T細胞依賴性免疫活化作用，能夠促進更強的記憶反應、持久保護，並且適合嬰幼兒等弱勢群體，因此該領域持續受到關注。

病毒性疾病領域在2024年佔據66.2%的市場佔有率，預計到2034年仍將保持強勁成長。此類別包括肝炎、流感、HPV、輪狀病毒、帶狀皰疹、麻疹、腮腺炎、德國麻疹、腮腺炎和德國麻疹疫苗（MMR）、新冠肺炎（COVID-19）以及其他病毒的疫苗。隨著認知和預防工作的不斷提升，免疫接種計畫在全球範圍內規模化，提高了覆蓋率和可及性。 mRNA和亞單位技術等生產平台的最新進展增強了病毒爆發期間的快速反應能力，支持了全球強力的公共衛生策略，並提高了各年齡層的接種率。

北美疫苗市場在2024年產值為323億美元，預計2034年將達到593億美元，複合年成長率為6.6%。該地區的領先地位源於其完善的醫療基礎設施、持續的公共免疫接種運動以及對預防保健的大量投入。持續的政策層面措施、高水準的認知度以及對HPV和其他病毒威脅疫苗的強勁需求，持續推動疫苗的銷售。美國已廣泛實施學校免疫接種計畫和成人免疫接種活動，提高了各人口的可近性和依從性。

為全球疫苗市場競爭格局做出貢獻的關鍵製造商包括賽諾菲、印度血清研究所、Valneva、CSL Seqirus、Emergent Biosolutions、輝瑞、Moderna、Novavax、葛蘭素史克 (GSK)、阿斯特捷利康、Biofarma、科興生物、Bharat Biotechharm、Haffkuine Bio-Penutical、VBIkacc.疫苗產業的領先公司正透過持續的研發投入，積極推進其產品線，尤其是在 mRNA、重組亞單位和基於載體的製劑等新型平台方面。

與生物技術公司、學術機構和政府衛生機構的合作與合資正在加速下一代疫苗的開發和監管批准。各公司也在全球擴大生產能力，以確保在疫情爆發期間快速實現規模化，並有效率地服務於服務不足的市場。策略性產品多元化，包括聯合疫苗和治療性疫苗的開發，正在幫助各公司應對更廣泛的疾病負擔。

目錄

第1章：方法論與範圍

第2章：執行摘要

第3章：行業洞察

  • 產業生態系統分析
  • 產業衝擊力
    • 成長動力
      • 傳染病發生率上升
      • 擴大免疫覆蓋計劃
      • 發展中經濟體兒科人口不斷增加
      • 疫苗配方和生產效率的進步
    • 產業陷阱與挑戰
      • 嚴格的法規核准流程
      • 疫苗儲存和運輸成本高
    • 市場機會
      • 擴大疫苗分發的公私部門合作夥伴關係
      • 聯合疫苗日益受到關注
  • 成長潛力分析
  • 技術格局
  • 管道分析
  • 監管格局
  • 未來市場趨勢
  • 波特的分析
  • PESTEL分析

第4章：競爭格局

  • 介紹
  • 公司矩陣分析
  • 公司市佔率分析
  • 主要市場參與者的競爭分析
  • 競爭定位矩陣
  • 關鍵進展
    • 併購
    • 夥伴關係和合作
    • 擴張計劃

第5章：市場估計與預測：按疫苗類型，2021-2034

  • 主要趨勢
  • 亞單位疫苗
    • 重組疫苗
    • 結合疫苗
    • 多醣體疫苗
  • 類毒素疫苗
  • 去活化疫苗
  • 減毒活疫苗
  • 其他疫苗類型

第6章：市場估計與預測：依疾病類型，2021-2034

  • 主要趨勢
  • 病毒性疾病
    • 肝炎
    • 流感
    • HPV
    • 麻疹、腮腺炎和德國麻疹 (MMR)
    • 輪狀病毒
    • 帶狀皰疹
    • 新冠肺炎
    • 其他病毒性疾病
  • 細菌性疾病
    • 腦膜炎球菌疾病
    • 肺炎球菌疾病
    • DPT
    • 其他細菌性疾病

第7章：市場估計與預測：依年齡層，2021-2034

  • 主要趨勢
  • 兒科
  • 成人

第8章：市場估計與預測：依最終用途，2021-2034

  • 主要趨勢
  • 醫院
    • 民眾
    • 私人的
  • 專科診所
  • 其他最終用途

第9章：市場估計與預測：按地區，2021-2034

  • 主要趨勢
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
    • 荷蘭
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第10章：公司簡介

  • AstraZeneca
  • Bharat Biotech
  • Biofarma
  • CSL Seqirus
  • Emergent Biosolutions
  • GlaxoSmithKline (GSK)
  • Haffkine Bio-Pharmaceutical
  • Merck
  • Moderna
  • Novavax
  • Pfizer
  • Sanofi
  • Serum Institute of India
  • Sinovac
  • Valneva
  • VBI Vaccines
簡介目錄
Product Code: 2186

The Global Vaccines Market was valued at USD 76.4 billion in 2024 and is estimated to grow at a CAGR of 7.1% to reach USD 145.8 billion by 2034. This growth is largely propelled by the continuous emergence of infectious diseases such as hepatitis, seasonal influenza, and novel virus strains. As these diseases remain a constant threat to public health, governments and health organizations are ramping up immunization efforts to reduce infection rates. Supportive public initiatives, increasing healthcare budgets in developing regions, and advancements in vaccine R&D continue to shape a favorable environment for expansion. Additionally, the global rise in combination vaccines, which deliver immunity for multiple diseases through a single dose, is accelerating innovation and simplifying immunization protocols.

Vaccines Market - IMG1

Development of next-generation vaccines targeting complex conditions such as cancers, chronic infections, and autoimmune diseases is expanding the market's therapeutic scope. A growing aging population, especially across developed nations, remains highly susceptible to infections, further fueling global vaccine demand. Strong collaborations between private firms and public health bodies, coupled with evolving technologies such as mRNA and recombinant protein platforms, are enhancing vaccine efficacy, delivery, and accessibility. Collectively, these factors are reinforcing long-term market momentum.

Market Scope
Start Year2024
Forecast Year2025-2034
Start Value$76.4 Billion
Forecast Value$145.8 Billion
CAGR7.1%

In 2024, subunit vaccines segment was valued at USD 37.6 billion and is estimated to reach USD 70.7 billion by 2034, growing at a CAGR of 6.9%. These vaccines include recombinant, polysaccharide, and conjugate types, each contributing to heightened immunogenicity without using whole pathogens. Their ability to target specific proteins from disease-causing organisms improves safety profiles and reduces unwanted immune responses. The segment continues to gain traction due to its T cell-dependent immune activation, which promotes stronger memory responses, long-lasting protection, and suitability for vulnerable populations like infants and young children.

The viral diseases segment held 66.2% share in 2024 and is expected to maintain strong growth through 2034. The category comprises vaccines for hepatitis, influenza, HPV, rotavirus, herpes zoster, MMR, COVID-19, and other viruses. As awareness and prevention efforts have expanded, immunization programs have scaled globally, improving coverage and access. Recent advancements in manufacturing platforms like mRNA and subunit technologies have enhanced rapid-response capabilities during viral outbreaks, supporting robust public health strategies worldwide and increasing uptake across all age groups.

North America Vaccines Market generated USD 32.3 billion in 2024 and is expected to reach USD 59.3 billion by 2034 at a CAGR of 6.6%. The region's leadership stems from its comprehensive healthcare infrastructure, ongoing public immunization campaigns, and significant investment in preventive care. Consistent policy-level initiatives, high levels of awareness, and strong demand for vaccines targeting HPV and other viral threats continue to drive sales. The U.S. has implemented widespread school-based programs and adult immunization drives, enhancing access and compliance across population segments.

Key manufacturers contributing to the competitive dynamics of the Global Vaccines Market include Sanofi, Serum Institute of India, Valneva, CSL Seqirus, Emergent Biosolutions, Pfizer, Moderna, Novavax, GlaxoSmithKline (GSK), AstraZeneca, Biofarma, Sinovac, Bharat Biotech, Haffkine Bio-Pharmaceutical, VBI Vaccines, and Merck. Leading companies in the vaccines sector are actively advancing their pipelines through sustained investments in R&D, particularly in novel platforms like mRNA, recombinant subunits, and vector-based formulations.

Partnerships and joint ventures with biotech firms, academic institutions, and government health agencies are helping expedite development and regulatory clearance for next-gen vaccines. Firms are also expanding production capabilities globally to ensure rapid scalability during outbreaks and to serve underserved markets efficiently. Strategic product diversification, including development of combination and therapeutic vaccines, is helping companies address broader disease burdens.

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market scope and definition
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Data mining sources
    • 1.3.1 Global
    • 1.3.2 Regional/country
  • 1.4 Base estimates and calculations
    • 1.4.1 Base year calculation
    • 1.4.2 Key trends for market estimation
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
  • 1.6 Forecast model
  • 1.7 Research assumptions and limitations

Chapter 2 Executive Summary

  • 2.1 Industry 360° synopsis
  • 2.2 Key market trends
    • 2.2.1 Regional
    • 2.2.2 Vaccine type
    • 2.2.3 Disease type
    • 2.2.4 Age group
    • 2.2.5 End use
  • 2.3 CXO perspectives: Strategic imperatives
    • 2.3.1 Key decision points for industry executives
    • 2.3.2 Critical success factors for market players
  • 2.4 Future outlook and strategic recommendations

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Rising incidence of infectious disease
      • 3.2.1.2 Growing immunization coverage programs
      • 3.2.1.3 Increasing pediatric population in developing economies
      • 3.2.1.4 Advancements in vaccine formulation and production efficiency
    • 3.2.2 Industry pitfalls and challenges
      • 3.2.2.1 Stringent regulatory approval processes
      • 3.2.2.2 High cost of storage and transportation of vaccine
    • 3.2.3 Market opportunities
      • 3.2.3.1 Expanding public-private partnerships for vaccine distribution
      • 3.2.3.2 Growing focus on combination vaccines
  • 3.3 Growth potential analysis
  • 3.4 Technology landscape
  • 3.5 Pipeline analysis
  • 3.6 Regulatory landscape
  • 3.7 Future market trends
  • 3.8 Porter’s analysis
  • 3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

  • 4.1 Introduction
  • 4.2 Company matrix analysis
  • 4.3 Company market share analysis
  • 4.4 Competitive analysis of major market players
  • 4.5 Competitive positioning matrix
  • 4.6 Key developments
    • 4.6.1 Mergers and acquisitions
    • 4.6.2 Partnerships and collaborations
    • 4.6.3 Expansion plans

Chapter 5 Market Estimates and Forecast, By Vaccine Type, 2021-2034 ($ Mn)

  • 5.1 Key trends
  • 5.2 Subunit vaccines
    • 5.2.1 Recombinant vaccines
    • 5.2.2 Conjugate vaccines
    • 5.2.3 Polysaccharide vaccines
  • 5.3 Toxoid vaccines
  • 5.4 Inactivated vaccines
  • 5.5 Live attenuated vaccines
  • 5.6 Other vaccine types

Chapter 6 Market Estimates and Forecast, By Disease Type, 2021-2034 ($ Mn)

  • 6.1 Key trends
  • 6.2 Viral diseases
    • 6.2.1 Hepatitis
    • 6.2.2 Influenza
    • 6.2.3 HPV
    • 6.2.4 Measles, mumps, and rubella (MMR)
    • 6.2.5 Rotavirus
    • 6.2.6 Herpes zoster
    • 6.2.7 Covid-19
    • 6.2.8 Other viral diseases
  • 6.3 Bacterial diseases
    • 6.3.1 Meningococcal diseases
    • 6.3.2 Pneumococcal diseases
    • 6.3.3 DPT
    • 6.3.4 Other bacterial diseases

Chapter 7 Market Estimates and Forecast, By Age Group, 2021-2034 ($ Mn)

  • 7.1 Key trends
  • 7.2 Pediatric
  • 7.3 Adult

Chapter 8 Market Estimates and Forecast, By End Use, 2021-2034 ($ Mn)

  • 8.1 Key trends
  • 8.2 Hospitals
    • 8.2.1 Public
    • 8.2.2 Private
  • 8.3 Specialty clinics
  • 8.4 Other end use

Chapter 9 Market Estimates and Forecast, By Region, 2021-2034 ($ Mn)

  • 9.1 Key trends
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 France
    • 9.3.4 Spain
    • 9.3.5 Italy
    • 9.3.6 Netherlands
  • 9.4 Asia Pacific
    • 9.4.1 China
    • 9.4.2 Japan
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 South Korea
  • 9.5 Latin America
    • 9.5.1 Brazil
    • 9.5.2 Mexico
    • 9.5.3 Argentina
  • 9.6 Middle East and Africa
    • 9.6.1 South Africa
    • 9.6.2 Saudi Arabia
    • 9.6.3 UAE

Chapter 10 Company Profiles

  • 10.1 AstraZeneca
  • 10.2 Bharat Biotech
  • 10.3 Biofarma
  • 10.4 CSL Seqirus
  • 10.5 Emergent Biosolutions
  • 10.6 GlaxoSmithKline (GSK)
  • 10.7 Haffkine Bio-Pharmaceutical
  • 10.8 Merck
  • 10.9 Moderna
  • 10.10 Novavax
  • 10.11 Pfizer
  • 10.12 Sanofi
  • 10.13 Serum Institute of India
  • 10.14 Sinovac
  • 10.15 Valneva
  • 10.16 VBI Vaccines